Wolverine Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$751K Buy
+10,000
New +$789K 0.01% 846
2020
Q3
Sell
-7,700
Closed -$453K 1652
2020
Q2
$453K Buy
+7,700
New +$428K ﹤0.01% 740
2020
Q1
Sell
-900
Closed -$54K 1555
2019
Q4
$54K Buy
+900
New +$53.6K ﹤0.01% 1177
2017
Q3
Sell
-25,000
Closed -$1.27M 1419
2017
Q2
$1.27M Buy
+25,000
New +$1.16M 0.02% 554
2016
Q3
Sell
-7,300
Closed -$170K 1276
2016
Q2
$170K Buy
+7,300
New +$235K ﹤0.01% 897
2014
Q1
Sell
-94
Closed -$49K 2615
2013
Q4
$49K Hold
94
﹤0.01% 1772
2013
Q3
$60K Buy
+94
New +$2.81K ﹤0.01% 1655

Other funds holding IONS

Wolverine Asset Management's IONS Position: Q1 2026 in Review

Wolverine Asset Management reduced its Ionis Pharmaceuticals (IONS) stake by 25% in Q1 2026, selling an estimated $608K and leaving 22,815 shares worth $1.71M. The position accounts for 0.02% of the portfolio, ranked #613.

Wolverine Asset Management first reported a position in IONS in Q4 2016 and has held it in 5 quarters since. The position peaked at $8.98M in Q4 2016. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Wolverine Asset Management held 22,815 shares of Ionis Pharmaceuticals worth $1.71M as of Q1 2026.
  • Wolverine Asset Management sold 7,700 Ionis Pharmaceuticals shares in Q1 2026, an estimated $608K.
  • Ionis Pharmaceuticals made up 0.02% of Wolverine Asset Management's portfolio in Q1 2026, its #613 holding.
  • Wolverine Asset Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 5 quarters since.
  • Wolverine Asset Management's Ionis Pharmaceuticals position peaked at $8.98M in Q4 2016.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.